Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in... Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California. Mostra di più
| Periodo † | Var | Var % | Apert. | Max | Min | Med. Vol. Giorn. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.075 | 3.5046728972 | 2.14 | 2.3189 | 2.05 | 747015 | 2.18643785 | CS |
| 4 | -0.605 | -21.4539007092 | 2.82 | 2.945 | 2.03 | 994607 | 2.4730968 | CS |
| 12 | 0.225 | 11.3065326633 | 1.99 | 2.945 | 1.845 | 2017888 | 2.32319287 | CS |
| 26 | -3.675 | -62.3938879457 | 5.89 | 6.52 | 1.845 | 1442401 | 2.76549124 | CS |
| 52 | -3.305 | -59.8731884058 | 5.52 | 7.25 | 1.845 | 1206564 | 3.63538 | CS |
| 156 | -20.785 | -90.3695652174 | 23 | 29.88 | 1.845 | 1172060 | 7.85566822 | CS |
| 260 | -20.785 | -90.3695652174 | 23 | 29.88 | 1.845 | 1172060 | 7.85566822 | CS |
Le azioni che visualizzerai appariranno in questo riquadro, così potrai facilmente tornare alle quotazioni di tuo interesse.
Assistenza: support@advfn.it
Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni
Caratteristiche principali
Premium
